Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Quantitative Pharmacodynamic Analysis of Trimethoprim-Sulfonamide Combination Activity Against Staphylococcus pseudintermedius.

Created on 09 Sep 2026

Authors

Andrew Mead, Alexis Viel, Marine Boulanger, Gudrun Overesch, Carl Ekstrand, Pierre-Louis Toutain, Aude A Ferran, Ludovic Pelligand

Published in

Journal of veterinary pharmacology and therapeutics. Sep 09, 2026. Epub Sep 09, 2026.

Abstract

Trimethoprim (TMP)-sulfonamide combinations are widely used in veterinary medicine, yet the quantitative nature of their pharmacodynamic interaction remains incompletely characterised. This study investigated the interaction between TMP and sulfamethoxazole (SMX), sulfadiazine (SDZ) and sulfadimethoxine (SDMX) against two Staphylococcus pseudintermedius isolates using minimum inhibitory concentration (MIC) testing, time-kill curve (TKC) experiments and semi-mechanistic pharmacodynamic modelling incorporating a General Pharmacodynamic Interaction (GPDI) framework. TKC assays demonstrated enhanced antibacterial activity for TMP-sulfonamide combinations compared with monotherapy, with the greatest bacterial killing observed at TMP:sulfonamide ratios of 1:4 and 1:19. The final GPDI model identified a predominantly unidirectional interaction in which sulfonamides increased TMP potency through concentration-dependent reductions in TMP EC50 of 86%-96% at saturating sulfonamide concentrations, corresponding to approximately 7- to 26-fold maximal possible increases in TMP potency. Maximal synergy differed between sulfonamides, occurring at approximately 1:20 for TMP/SMX (~75% increase in killing), 1:40 for TMP/SDZ (~181%) and 1:5 for TMP/SDMX (~80%). Pharmacokinetic-pharmacodynamic simulations of clinically relevant canine dosing regimens predicted transient bacterial suppression but not bacterial eradication. These findings demonstrate that TMP-sulfonamide synergy is dynamic, concentration-dependent and bacterial species-specific, highlighting the importance of PK/PD-informed optimisation of potentiated sulfonamide therapy in veterinary medicine.

PMID:
42714374
Bibliographic data and abstract were imported from PubMed on 09 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement